Leede Financial Has Negative View of TSE:MDP FY2026 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDP) – Analysts at Leede Financial reduced their FY2026 EPS estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. Leede Financial analyst D. Loe now anticipates that the company will earn $0.14 per share for the year, down from their prior forecast of $0.21. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2027 earnings at $0.51 EPS and FY2028 earnings at $0.82 EPS.

Separately, Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 11th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat, Medexus Pharmaceuticals presently has an average rating of “Buy” and an average target price of C$5.49.

Medexus Pharmaceuticals Stock Performance

Shares of Medexus Pharmaceuticals stock opened at C$2.95 on Thursday. The firm has a market cap of C$66.05 million, a PE ratio of 14.11 and a beta of 1.96. The firm’s 50-day simple moving average is C$2.92 and its 200-day simple moving average is C$2.81. Medexus Pharmaceuticals has a 1 year low of C$1.71 and a 1 year high of C$5.56.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.